Short Interest in Nanovibronix, Inc. (NASDAQ:FEED) Rises By 1,387.8%

Posted by on May 29th, 2026

Nanovibronix, Inc. (NASDAQ:FEED – Get Free Report) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 163,391 shares, an increase of 1,387.8% from the April 30th total of 10,982 shares. Based on an average daily trading volume, of 982,721 shares, the short-interest ratio is presently 0.2 days. Currently, 2.7% of the company’s shares are sold short.

Nanovibronix Stock Performance

Shares of NASDAQ FEED traded down $0.02 during midday trading on Friday, reaching $0.90. The stock had a trading volume of 122,152 shares, compared to its average volume of 7,780,990. The company has a market cap of $5.49 million, a price-to-earnings ratio of -0.10 and a beta of 1.59. Nanovibronix has a twelve month low of $0.84 and a twelve month high of $17.40. The firm has a 50 day simple moving average of $1.48.

Nanovibronix (NASDAQ:FEED – Get Free Report) last issued its quarterly earnings results on Monday, May 18th. The company reported ($6.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.65 million during the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.

Analysts Set New Price Targets

Several research firms recently commented on FEED. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Get Our Latest Research Report on FEED

Nanovibronix Company Profile

(Get Free Report)

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.

Featured Articles

Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.